PharmaSGP Holding SE (PSG.F)
- Previous Close
22.00 - Open
22.00 - Bid 22.00 x --
- Ask 22.40 x --
- Day's Range
22.00 - 22.00 - 52 Week Range
18.00 - 28.80 - Volume
100 - Avg. Volume
18 - Market Cap (intraday)
263.784M - Beta (5Y Monthly) 0.06
- PE Ratio (TTM)
17.60 - EPS (TTM)
1.25 - Earnings Date Apr 29, 2024
- Forward Dividend & Yield 0.49 (2.23%)
- Ex-Dividend Date Jun 29, 2023
- 1y Target Est
--
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for treatment of hair loss; Dorisol, a pain relies tablet; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten, for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness and mood swings; Deruba, a cream for skin redness; Lentisol prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.
pharmasgp.com79
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PSG.F
Performance Overview: PSG.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PSG.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PSG.F
Valuation Measures
Market Cap
261.39M
Enterprise Value
224.34M
Trailing P/E
17.60
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.71
Price/Book (mrq)
7.21
Enterprise Value/Revenue
2.30
Enterprise Value/EBITDA
6.72
Financial Highlights
Profitability and Income Statement
Profit Margin
15.37%
Return on Assets (ttm)
10.96%
Return on Equity (ttm)
46.75%
Revenue (ttm)
97.55M
Net Income Avi to Common (ttm)
14.99M
Diluted EPS (ttm)
1.25
Balance Sheet and Cash Flow
Total Cash (mrq)
38.05M
Total Debt/Equity (mrq)
213.33%
Levered Free Cash Flow (ttm)
19.5M
Company Insights: PSG.F
PSG.F does not have Company Insights